Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Cancer Chemotherapy and Pharmacology
Published in: Cancer Chemotherapy and Pharmacology 1/2000

01-06-2000 | ORIGINAL ARTICLE

Evaluation of toremifene for reversal of multidrug resistance in renal cell cancer patients treated with vinblastine

Authors: Jeremy P. Braybrooke, Katherine A. Vallis, Susan Houlbrook, Helen Rockett, Juha Ellmén, Markku Anttila, Trivadi S. Ganesan, Adrian L. Harris, Denis C. Talbot

Published in: Cancer Chemotherapy and Pharmacology | Issue 1/2000

Login to get access
Metadata
Title
Evaluation of toremifene for reversal of multidrug resistance in renal cell cancer patients treated with vinblastine
Authors
Jeremy P. Braybrooke
Katherine A. Vallis
Susan Houlbrook
Helen Rockett
Juha Ellmén
Markku Anttila
Trivadi S. Ganesan
Adrian L. Harris
Denis C. Talbot
Publication date
01-06-2000
Publisher
Springer-Verlag
Published in
Cancer Chemotherapy and Pharmacology / Issue 1/2000
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI
https://doi.org/10.1007/s002809900085

Other articles of this Issue 1/2000

Cancer Chemotherapy and Pharmacology 1/2000 Go to the issue

ORIGINAL ARTICLE

Reduction of 5-fluorouracil (5-FU) gastrointestinal (GI) toxicity resulting from the protection of thymidylate synthase (TS) in GI tissue by repeated simultaneous administration of potassium oxonate (Oxo) in rats

ORIGINAL ARTICLE

Pharmacokinetics of 2-chloro-2′-deoxyadenosine administered subcutaneously or by continuous intravenous infusion

ORIGINAL ARTICLE

Primary treatment of low-grade non-Hodgkin's lymphoma using an all oral anthracycline-containing regimen, chlorambucil, idarubicin, dexamethasone (CID) – a phase II study

ORIGINAL ARTICLE

Effects of the aromatase inhibitor anastrozole on serum oestrogens in Japanese and Caucasian women

ORIGINAL ARTICLE

A novel synthetic DNA minor groove binder, MS-247: antitumor activity and cytotoxic mechanism

ORIGINAL ARTICLE

Feasibility and pharmacokinetics of intraperitoneal suramin in advanced malignancy
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits